SG11201810694WA - Use of biomarkers in determining susceptibility to disease treatment - Google Patents

Use of biomarkers in determining susceptibility to disease treatment

Info

Publication number
SG11201810694WA
SG11201810694WA SG11201810694WA SG11201810694WA SG11201810694WA SG 11201810694W A SG11201810694W A SG 11201810694WA SG 11201810694W A SG11201810694W A SG 11201810694WA SG 11201810694W A SG11201810694W A SG 11201810694WA SG 11201810694W A SG11201810694W A SG 11201810694WA
Authority
SG
Singapore
Prior art keywords
singapore
international
cancer
oncogene
genetic alteration
Prior art date
Application number
SG11201810694WA
Inventor
Narayanan Gopalakrishna Iyer
Daniel Shao-Weng Tan
Original Assignee
Singapore Health Serv Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Health Serv Pte Ltd filed Critical Singapore Health Serv Pte Ltd
Publication of SG11201810694WA publication Critical patent/SG11201810694WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111111111111 IIIIIIIII10101111111111111110111011111111011111111011110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/209697 Al 07 December 2017 (07.12.2017) WIP0 I PCT (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, C12Q 1/68 (2006.01) KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/SG2017/050284 Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) (22) International Filing Date: 05 June 2017 (05.06.2017) Published: — with international search report (Art. 21(3)) (25) Filing Language: English — with sequence listing part of description (Rule 5.2(a)) (26) Publication Language: English (30) Priority Data: 62/345,081 03 June 2016 (03.06.2016) US (71) Applicant: SINGAPORE HEALTH SERVICES PTE LTD [SG/SG]; 31 Third Hospital Avenue, #03-03, Bowyer Block C, Singapore 168753 (SG). (72) Inventors: IYER, Narayanan Gopalakrishna; c/o Na- tional Cancer Centre Singapore, 11 Hospital Drive, Singa- pore 169610 (SG). TAN, Daniel Shao-Weng; c/o Nation- — al Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610 (SG). — = (74) Agent: SPRUSON & FERGUSON (ASIA) PTE LTD; = P.O. Box 1531, Robinson Road Post Office, Singapore 903031 (SG). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, = HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, = KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, = MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, = = PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, = SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = = = Designated States indicated, (84) (unless otherwise for every = kind of regional protection available): ARIPO (BW, GH, = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = ZM, ZW), Eurasian AZ, BY, KG, KZ, RU, TJ, UG, (AM, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = — EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, = MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 1-1 N (54) Title: USE OF BIOMARKERS IN DETERMINING SUSCEPTIBILITY TO DISEASE TREATMENT (57) : The present invention refers to a method of predicting susceptibility of a subject suffering from cancer to a treatment ON with an anti-cancer drug, wherein the method comprises detecting the presence or absence of a genetic alteration in a long non-coding N RNA (IncRNA) that resides in an antisense strand of an oncogene, wherein the genetic alteration disrupts expression of the oncogene, ---. and wherein the subject is predicted to be more susceptible to the treatment if the genetic alteration is present. In particular, the genetic I N alteration is a silent G>A mutation at Q787Q of the oncogene epidermal growth factor receptor (EGFR). Also disclosed herein is a 1-1 © method of treating a subject suffering from cancer, who was shown to have a genetic alteration in IncRNA that resides in an antisense ei strand of an oncogene. C
SG11201810694WA 2016-06-03 2017-06-05 Use of biomarkers in determining susceptibility to disease treatment SG11201810694WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662345081P 2016-06-03 2016-06-03
PCT/SG2017/050284 WO2017209697A1 (en) 2016-06-03 2017-06-05 Use of biomarkers in determining susceptibility to disease treatment

Publications (1)

Publication Number Publication Date
SG11201810694WA true SG11201810694WA (en) 2018-12-28

Family

ID=60478959

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810694WA SG11201810694WA (en) 2016-06-03 2017-06-05 Use of biomarkers in determining susceptibility to disease treatment

Country Status (5)

Country Link
US (1) US11274348B2 (en)
EP (1) EP3464638B1 (en)
CN (1) CN109563549B (en)
SG (1) SG11201810694WA (en)
WO (1) WO2017209697A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109880902B (en) * 2018-10-11 2022-10-28 中国药科大学 Application of long-chain non-coding RNA RP11-499F3.2 in reversing drug-resistant treatment of tumor cetuximab
CN109913554A (en) * 2019-04-15 2019-06-21 德阳市人民医院 A kind of lncRNA marker relevant to breast cancer
CN110302197A (en) * 2019-07-26 2019-10-08 安徽医科大学第一附属医院 A kind of lncRNA relevant to the miscellaneous Shandong amine therapeutic sensitivity of grace and its application in the miscellaneous Shandong amine treatment prostate cancer of grace
CN110846417B (en) * 2019-12-10 2021-09-17 湖南省肿瘤医院 Diagnosis and treatment marker for head and neck squamous cell carcinoma
US20230057430A1 (en) * 2020-01-13 2023-02-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibition of tap63 regulated oncogenic long non-coding rnas (trolls) in the treatment of cancer
CN113667747A (en) * 2020-05-14 2021-11-19 长庚大学 Method for treating oral cancer
JP2023539850A (en) * 2020-08-25 2023-09-20 シンガポール ヘルス サービシーズ ピーティーイー リミテッド How to modulate sensitivity to tyrosine kinase inhibitors
WO2022130259A2 (en) * 2020-12-16 2022-06-23 Cambridge Enterprise Limited Treatment of cancer associated with dysregulated novel open reading frame products
US20240060070A1 (en) * 2020-12-16 2024-02-22 Cambridge Enterprise Limited Treatment of cancer associated with variant novel open reading frames
CN113564255A (en) * 2021-08-13 2021-10-29 河北医科大学第四医院 Application of lncRNA NEAT1_1
CN114164209B (en) * 2021-08-19 2024-09-03 上海海洋大学 Tumor-related long-chain non-coding RNA, cDNA and application thereof
CN113621614B (en) * 2021-09-09 2023-08-11 天津医科大学总医院 Long-chain non-coding RNA and application thereof as MDS molecular marker
CN113817820B (en) * 2021-11-02 2022-05-06 江苏省人民医院（南京医科大学第一附属医院） Primer group and kit for evaluating sirolimus drug metabolism and evaluation method
CN114652737B (en) * 2022-05-18 2022-08-30 浙江省肿瘤医院 Application of non-coding RNA SNHG17 as marker and therapeutic target
CN116597902B (en) * 2023-04-24 2023-12-01 浙江大学 Method and device for screening multiple groups of chemical biomarkers based on drug sensitivity data

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101193905B (en) * 2005-02-11 2014-06-25 纪念斯隆-凯特林癌症中心 Methods and compositions for detecting a drug resistant EGFR mutant
SG10201510086VA (en) * 2010-12-23 2016-01-28 Nestec Sa Drug selection for malignant cancer therapy using antibody-based arrays

Also Published As

Publication number Publication date
CN109563549B (en) 2023-07-14
EP3464638A4 (en) 2020-02-12
WO2017209697A1 (en) 2017-12-07
EP3464638B1 (en) 2023-12-06
EP3464638C0 (en) 2023-12-06
US11274348B2 (en) 2022-03-15
EP3464638A1 (en) 2019-04-10
US20200318196A1 (en) 2020-10-08
WO2017209697A9 (en) 2018-12-20
CN109563549A (en) 2019-04-02

Similar Documents

Publication Publication Date Title
SG11201810694WA (en) Use of biomarkers in determining susceptibility to disease treatment
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201903928WA (en) Mesenchymal stem cells populations, their products, and use thereof
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201907451XA (en) Substituted imidazo-quinolines as nlrp3 modulators
SG11201808990QA (en) Compositions for topical application of compounds
SG11201903697WA (en) Liver organoid compositions and methods of making and using same
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201806609TA (en) Cancer evolution detection and diagnostic
SG11201407669QA (en) Methods for improving safety of blood-brain barrier transport
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201806432PA (en) Methods for assessing risk of developing colorectal cancer
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201408383SA (en) Methods of detecting diseases or conditions using circulating diseased cells
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201901172QA (en) A method for manufacturing a fuel component
SG11201810670VA (en) Use of mi r-198 in treating and diagnosing cutaneous squamous cell carcinoma
SG11201408434QA (en) Targeted rna-seq methods and materials for the diagnosis of prostate cancer
SG11201910195WA (en) Methods for trapping and barcoding discrete biological units in hydrogel
SG11201810019RA (en) Methods of human leukocyte antigen typing
SG11201803643TA (en) Virulence attenuated bacteria for treatment of malignant solid tumors